Cited In for PMID: 12941312

Year	Number of Results
2003	1
2005	1
2006	2
2009	1
2010	1
2011	1
2012	2
2014	1
2015	1
2023	1
2024	0

1

Cyclin-dependent kinase 4 inhibitors as a treatment for cancer. Part 2: identification and optimisation of substituted 2,4-bis anilino pyrimidines.

Breault GA, Ellston RP, Green S, James SR, Jewsbury PJ, Midgley CJ, Pauptit RA, Minshull CA, Tucker JA, Pease JE. Breault GA, et al. Bioorg Med Chem Lett. 2003 Sep 15;13(18):2961-6. doi: 10.1016/s0960-894x(03)00203-8. Bioorg Med Chem Lett. 2003. PMID: 12941312

2

Recent Progress in CDK4/6 Inhibitors and PROTACs.

Wang H, Ba J, Kang Y, Gong Z, Liang T, Zhang Y, Qi J, Wang J. Wang H, et al. Molecules. 2023 Dec 13;28(24):8060. doi: 10.3390/molecules28248060. Molecules. 2023. PMID: 38138549 Free PMC article. Review.

3

5-Substituted 2-amino-4,6-dihydroxypyrimidines and 2-amino-4,6-dichloropyrimidines: synthesis and inhibitory effects on immune-activated nitric oxide production.

Jansa P, Holý A, Dračínský M, Kolman V, Janeba Z, Kostecká P, Kmoníčková E, Zídek Z. Jansa P, et al. Med Chem Res. 2014;23(10):4482-4490. doi: 10.1007/s00044-014-1018-9. Epub 2014 May 9. Med Chem Res. 2014. PMID: 32214763 Free PMC article.

4

Pd(OAc)2-catalyzed dehydrogenative C-H activation: An expedient synthesis of uracil-annulated β-carbolinones.

Mondal B, Hazra S, Panda TK, Roy B. Mondal B, et al. Beilstein J Org Chem. 2015 Aug 4;11:1360-6. doi: 10.3762/bjoc.11.146. eCollection 2015. Beilstein J Org Chem. 2015. PMID: 26425190 Free PMC article.

5

Development of o-chlorophenyl substituted pyrimidines as exceptionally potent aurora kinase inhibitors.

Lawrence HR, Martin MP, Luo Y, Pireddu R, Yang H, Gevariya H, Ozcan S, Zhu JY, Kendig R, Rodriguez M, Elias R, Cheng JQ, Sebti SM, Schonbrunn E, Lawrence NJ. Lawrence HR, et al. J Med Chem. 2012 Sep 13;55(17):7392-7416. doi: 10.1021/jm300334d. Epub 2012 Aug 30. J Med Chem. 2012. PMID: 22803810 Free PMC article.

6

Substantial improvements in large-scale redocking and screening using the novel HYDE scoring function.

Schneider N, Hindle S, Lange G, Klein R, Albrecht J, Briem H, Beyer K, Claußen H, Gastreich M, Lemmen C, Rarey M. Schneider N, et al. J Comput Aided Mol Des. 2012 Jun;26(6):701-23. doi: 10.1007/s10822-011-9531-0. Epub 2011 Dec 27. J Comput Aided Mol Des. 2012. PMID: 22203423

7

A myosin V inhibitor based on privileged chemical scaffolds.

Islam K, Chin HF, Olivares AO, Saunders LP, De La Cruz EM, Kapoor TM. Islam K, et al. Angew Chem Int Ed Engl. 2010 Nov 2;49(45):8484-8. doi: 10.1002/anie.201004026. Angew Chem Int Ed Engl. 2010. PMID: 20878825 Free PMC article. No abstract available.

8

Novel mutant-selective EGFR kinase inhibitors against EGFR T790M.

Zhou W, Ercan D, Chen L, Yun CH, Li D, Capelletti M, Cortot AB, Chirieac L, Iacob RE, Padera R, Engen JR, Wong KK, Eck MJ, Gray NS, Jänne PA. Zhou W, et al. Nature. 2009 Dec 24;462(7276):1070-4. doi: 10.1038/nature08622. Nature. 2009. PMID: 20033049 Free PMC article.

9

Feature-map vectors: a new class of informative descriptors for computational drug discovery.

Landrum GA, Penzotti JE, Putta S. Landrum GA, et al. J Comput Aided Mol Des. 2006 Dec;20(12):751-62. doi: 10.1007/s10822-006-9085-8. Epub 2007 Jan 5. J Comput Aided Mol Des. 2006. PMID: 17205374

10

The effect of a tightly bound water molecule on scaffold diversity in the computer-aided de novo ligand design of CDK2 inhibitors.

García-Sosa AT, Mancera RL. García-Sosa AT, et al. J Mol Model. 2006 Mar;12(4):422-31. doi: 10.1007/s00894-005-0063-1. Epub 2005 Dec 23. J Mol Model. 2006. PMID: 16374623

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Results by year

Text availability

Article attribute

Article type

Publication date

10 results

Results by year